Illumina to divest cancer test maker Grail
The divestiture will be executed through a third-party sale or capital markets transaction, San Diego-based Illumina said in a statement, adding that it would finalize the terms by second quarter of 2024.
Top tags
Today most read articles
Article
Similar articles